Eli Lilly and Co. has reached a resolution with the U.S. Attorney for the Eastern District of Pennsylvania (EDPA) and the Office of Consumer Litigation of the Department of Justice regarding the government investigation into the company’s marketing and promotional practices for antipsychotic drug Zyprexa. Lilly has agreed to plead guilty to one misdemeanor violation of the Food, Drug, and Cosmetic Act for the off-label promotion of Zyprexa between September of 1999 and March of 2001. T...